HindBio Science Stock Price Today (NSE: HINDIBIO)

HindBio Science

7.40+0.00 (+0.00%)
Market Closed

Fundamental Score

...

HindBio Science Share Price — Live NSE/BSE Price, Fundamentals & Analysis

HindBio Science share price today is 7.40, up +0.00% on NSE/BSE as of 1 August 2026. HindBio Science (HINDIBIO) is a Small-cap company in the Software Products sector with a market capitalisation of 7.59 (Cr). The 52-week high for HINDIBIO share price is N/A and the 52-week low is N/A. The company has a Return on Equity (ROE) of -9.25% and a debt-to-equity ratio of 2.83.

HindBio Science Share Price Chart — NSE/BSE Historical Performance

No data
High
7.40
Low
7.40
Volume
0
Change
+0.00%

HindBio Science share price chart: 0.00% return over the past month. 52-week high ₹N/A, 52-week low ₹N/A.

AI Research Briefing

Powered by Gemini · 2026-08-01

A zero-revenue micro-cap shell bleeding capital with 2.83x D/E and 12.19% promoter skin in the game.

Research Confidence
1.0/10Low
MICRO-CAP DARK HORSEBreakdown with 1M return at -5.73% and 3M return at -15.91%.Expensive and unviable; P/E is non-existent due to persistent net losses versus industry P/E of 34.85x.

WHAT'S HAPPENING NOW (last 2-4 weeks)

Hindustan Bio Sciences delivered another operational blank in Q1 FY27 (quarter ended June 2026), posting ₹0.00 crore in sales (-100% YoY) and a net loss of ₹0.11 crore compared to a net profit of ₹0.01 crore in June 2025. This follows a quarter ended March 2026 where sales were also zero with a net loss of ₹0.12 crore, dragging full-year FY26 sales down 8.64% to ₹0.74 crore. Management turbulence persists with Company Secretary Devanshu Dange resigning effective July 31, 2026, replaced by Shailendra Vyas on August 1, 2026.

CORE STORY (THE REAL GAME)

This is a micro-cap shell with severe fundamental distress, not a viable software or biotech growth play. The business repeatedly hits zero top-line quarters while bleeding cash on fixed expenses and interest overheads.

Why Now
  • Q1 FY27 reported ₹0.00 Cr sales with a net loss of ₹0.11 Cr
  • Resignation of Key Managerial Personnel (Company Secretary) effective July 31, 2026
  • FY26 total sales down to ₹0.74 Cr with full-year loss of ₹0.08 Cr
Potential Catalysts
  • Potential capital infusion or promoter stake purchase
  • Insolvency/debt restructuring announcements
  • Speculative micro-cap momentum spikes on low volume
Key Risks
  • Zero revenue reported in consecutive quarters (March & June 2026)
  • High leverage with Debt/Equity at 2.83x and negative ROE of -9.25%
  • Micro/SME cap with severe illiquidity risk and 12.19% promoter holding
Institutional Activity

Zero institutional interest (0.0% FII, 0.0% DII); promoter holding stagnant at a low 12.19% with zero net change.

Macro Context

Broader tech and software product sectors require scale and R&D capital, leaving capital-starved micro-caps vulnerable to total obsolescence.

Order Book / Expansion

No major order wins found after live search; sales collapsed to ₹0.00 Cr in latest quarter.

Cash Flow Quality

No — negative cash generation with 5Y cumulative FCF of ₹-1.5 Cr.

3–6 Month Outlook

High risk of further capital erosion and insolvency without immediate revenue revival or external capital injection.

Primary Thesis Risk

Persistent zero-revenue quarters leading to debt default or corporate restructuring.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

-9.25%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

-2.43%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

-11.14%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

HindBio Science Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.85x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Good

Promoter Holding

12.19%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-209.09%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-100.00%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

-6.40%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

13.88%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

13.88%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

2.83x

Total debt ÷ equity. Below 0.5 = financially healthy

Interest Coverage Ratio

N/A

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-1.50 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

HindBio Science Fundamental Analysis & Valuation Benchmarking

Educational evaluation of HINDIBIO across key market metrics for learning purposes.

Positive Indicators

1 factors identified

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

10 factors identified

Below-Average Return on Equity (-9.25%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (-2.43%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Margin Pressure Concerns (-11.14%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges.

Profit Decline Concern (-209.09%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Revenue Contraction (-100.00%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Limited Growth History (-6.40% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Elevated Debt Levels (D/E: 2.83)

Observation: High leverage increases financial risk and interest burden.

Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.

Negative Free Cash Flow (₹-1.50 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Low Promoter Commitment (12.19%)

Observation: Reduced promoter stake may indicate limited confidence.

Analysis: Low promoter holding may raise questions about management commitment.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

HindBio Science vs Software Products Peers

Peer Comparison - Software Products

Compare HindBio Science with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
0.3/100
7
₹7.59
-9.25%
Poor
-2.43%
Poor
2.8
Poor
13.88%
Good
-6.40%
Poor
0.00%
63.3/100
11186
₹101190.51
38.3
Average
32.61%
Excellent
45.28%
Excellent
0.0
Excellent
8.42%
Good
9.01%
Good
3.44%
65.5/100
587
₹7484.41
14.7
Average
21.41%
Excellent
26.32%
Excellent
0.0
Excellent
7.50%
Good
13.54%
Good
2.13%
59.2/100
1182
₹6444.54
48.0
Average
15.82%
Good
22.00%
Excellent
0.0
Excellent
22.86%
Excellent
25.47%
Excellent
0.30%
48.2/100
581
₹3060.85
51.0
Average
18.04%
Good
19.33%
Good
0.1
Excellent
1.47%
Average
2.28%
Average
0.00%
43.2/100
1181
₹2424.83
82.6
Average
55.54%
Excellent
75.89%
Excellent
0.1
Excellent
0.06%
47.2/100
686
₹2011.39
17.9
Average
13.08%
Average
16.83%
Good
0.0
Excellent
1.95%
Average
11.27%
Good
1.64%
21.6/100
20
₹1994.78
33.0
Average
11.58%
Average
14.16%
Average
0.3
Excellent
0.00%
21.9/100
88
₹965.01
47.2
Average
15.55%
Good
21.09%
Excellent
0.1
Excellent
0.00%
14.2/100
153
₹897.35
-2.49%
Poor
-4.65%
Poor
0.0
Excellent
-4.76%
Poor
0.00%
Subex Ltd...
SUBEXLTD532348
29.7/100
12
₹757.62
23.6
Average
9.91%
Poor
13.07%
Average
0.1
Excellent
-8.46%
Poor
-5.59%
Poor
0.00%

HindBio Science Quarterly Performance

Latest quarterly metrics for HINDIBIO — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-100.00%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-209.09%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

-6.40%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

13.88%

Compounded annual net profit growth over 5 years

HindBio Science Financial Statements

Annual income statement, balance sheet and cash flow for HindBio Science (HINDIBIO) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for HindBio Science

About HINDIBIO (HindBio Science)

HindBio Science (HINDIBIO) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Software Products sector with a curr...ent market capitalisation of ₹7.59 (Cr). HindBio Science has delivered a Return on Equity (ROE) of -9.25% and a ROCE of -2.43%. The debt-to-equity ratio stands at 2.83, reflecting the company's capital structure. Investors tracking HINDIBIO share price can monitor key metrics including P/E ratio, promoter holding of 12.19%, and quarterly earnings growth.

Company Details

Symbol:HINDIBIO
Industry:Software Products
Sector:Software Products
Website:N/A

HINDIBIO Share Price: Frequently Asked Questions

What is the current share price of HindBio Science?

HindBio Science (HINDIBIO) trades at ₹7.40 on NSE and BSE. Market cap ₹7.59 (Cr). Educational data only.

What is the P/E ratio of HindBio Science?

HindBio Science has a P/E of N/Ax vs industry average 34.85x.

What is the Bull Run score for HindBio Science?

HindBio Science has a Bull Run score of 0.3/100 based on 25+ financial parameters.

Does HindBio Science pay dividends?

HindBio Science has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of HindBio Science?

HindBio Science has ROE of -9.25%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of HindBio Science?

HindBio Science has debt-to-equity of 2.83.

Is HindBio Science a good investment?

Bull Run gives HindBio Science a score of 0.3/100. This is not investment advice — consult a SEBI-registered advisor.